The retention and expansion checklist: 25 things to have in place for healthcare and life sciences in the Middle East
A single-page checklist to audit whether your retention and expansion setup is production-grade or a science project. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the Middle East.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Middle East. In this market, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing, so the way you install retention and expansion has to be shaped to that reality from day one.
Use this as a pre-flight before you commit spend to retention and expansion. Each item takes minutes to check and hours to fix later.
List, trigger, message. If any of the three is generic, stop and fix the generic one before you touch the other two. Generic list plus sharp message beats sharp list plus generic message, but only for a week.
Owner, cadence, metric. One named human owns the model. The cadence is written down. Gross and net revenue retention is the number in every review.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Middle East it is compounded by the fact that senior-relationship access, not product is what actually gates growth. Retention and expansion is only useful here when it is pointed at both constraints at once.
Data, tooling, workflow. Data flows to one place. Tooling is minimal. Workflow survives the owner going on holiday.
Quality gate, kill criteria, learning loop. Nothing ships without a human eyeballing it. Anything below the bar dies inside a week. What you learn feeds Monday.
Ethics, brand, deliverability. You will not do anything on this list you would not want on the front page. Brand is protected. Sending infrastructure is separated from the primary domain.
Governance, budget, escalation path. Someone above the owner cares. Budget is finite and defended. Bad news travels up in hours, not weeks.
If more than three of these are missing, retention and expansion is not going to produce a durable gross and net revenue retention. Fix them in order and re-run the checklist in a month.
Concretely for healthcare and life sciences in the Middle East: the healthcare teams that install this get past procurement instead of dying in it, and one sovereign or family-office win in the Middle East justifies a full year of program spend. That is the reason it is worth installing retention and expansion deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Retention · healthcare · Middle East — answered
- Does retention and expansion work for healthcare and life sciences in the Middle East?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the Middle East, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing. The healthcare teams that install this get past procurement instead of dying in it.
- How often should I run this checklist?
- Quarterly, plus any time you change ownership, tooling, or budget for retention and expansion.
- What is the single most important item?
- A named owner. Every other item is meaningless without one.
- What if I fail more than three items?
- Pause the spend, fix them in order, and restart at low volume rather than push through.
- Does this checklist apply at enterprise scale?
- Yes — the items are the same. Governance and escalation matter more at scale.
- What is the Middle East-specific pitfall when running retention and expansion for healthcare?
- Importing a playbook that was built for another market. In the Middle East, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing — the install has to reflect that.
Growth Broker editorial
Filed under retention · healthcare · middle east